Literature DB >> 17057098

Protection elicited by two glutamine auxotrophs of Mycobacterium tuberculosis and in vivo growth phenotypes of the four unique glutamine synthetase mutants in a murine model.

Sunhee Lee1, Bo-Young Jeon, Svetoslav Bardarov, Mei Chen, Sheldon L Morris, William R Jacobs.   

Abstract

We generated four individual glutamine synthetase (GS) mutants (DeltaglnA1, DeltaglnA2, DeltaglnA3, and DeltaglnA4) and one triple mutant (DeltaglnA1EA2) of Mycobacterium tuberculosis to investigate the roles of GS enzymes. Subcutaneous immunization with the DeltaglnA1EA2 and DeltaglnA1 glutamine auxotrophic mutants conferred protection on C57BL/6 mice against an aerosol challenge with virulent M. tuberculosis, which was comparable to that provided by Mycobacterium bovis BCG vaccination.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17057098      PMCID： PMC1695480          DOI： 10.1128/IAI.00531-06

Source DB:  PubMed          Journal:  Infect Immun        ISSN： 0019-9567            Impact factor:   3.441


  27 in total

1.  Long-term protection against tuberculosis following vaccination with a severely attenuated double lysine and pantothenate auxotroph of Mycobacterium tuberculosis.

Authors:  Vasan K Sambandamurthy; Steven C Derrick; Kripa V Jalapathy; Bing Chen; Robert G Russell; Sheldon L Morris; William R Jacobs
Journal:  Infect Immun       Date:  2005-02       Impact factor: 3.441

2.  Use of the mycobacteriophage L5 excisionase in Mycobacterium tuberculosis to demonstrate gene essentiality.

Authors:  T Parish; J Lewis; N G Stoker
Journal:  Tuberculosis (Edinb)       Date:  2001       Impact factor: 3.131

3.  Persistence and protective efficacy of a Mycobacterium tuberculosis auxotroph vaccine.

Authors:  M Jackson; S W Phalen; M Lagranderie; D Ensergueix; P Chavarot; G Marchal; D N McMurray; B Gicquel; C Guilhot
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

4.  All four Mycobacterium tuberculosis glnA genes encode glutamine synthetase activities but only GlnA1 is abundantly expressed and essential for bacterial homeostasis.

Authors:  Günter Harth; Sasa Maslesa-Galić; Michael V Tullius; Marcus A Horwitz
Journal:  Mol Microbiol       Date:  2005-11       Impact factor: 3.501

Review 5.  New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development.

Authors:  Arun T Kamath; Uli Fruth; Michael J Brennan; Roland Dobbelaer; Peter Hubrechts; Mei Mei Ho; Ronald E Mayner; Jelle Thole; K Barry Walker; Margaret Liu; Paul-Henri Lambert
Journal:  Vaccine       Date:  2005-03-24       Impact factor: 3.641

6.  Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

Authors:  A Pablos-Méndez; M C Raviglione; A Laszlo; N Binkin; H L Rieder; F Bustreo; D L Cohn; C S Lambregts-van Weezenbeek; S J Kim; P Chaulet; P Nunn
Journal:  N Engl J Med       Date:  1998-06-04       Impact factor: 91.245

7.  A pantothenate auxotroph of Mycobacterium tuberculosis is highly attenuated and protects mice against tuberculosis.

Authors:  Vasan K Sambandamurthy; Xiaojuan Wang; Bing Chen; Robert G Russell; Steven Derrick; Frank M Collins; Sheldon L Morris; William R Jacobs
Journal:  Nat Med       Date:  2002-09-09       Impact factor: 53.440

8.  Adenylylation and catalytic properties of Mycobacterium tuberculosis glutamine synthetase expressed in Escherichia coli versus mycobacteria.

Authors:  Ranjana Mehta; Josh T Pearson; Sumit Mahajan; Abhinav Nath; Mark J Hickey; David R Sherman; William M Atkins
Journal:  J Biol Chem       Date:  2004-03-22       Impact factor: 5.157

9.  An inhibitor of exported Mycobacterium tuberculosis glutamine synthetase selectively blocks the growth of pathogenic mycobacteria in axenic culture and in human monocytes: extracellular proteins as potential novel drug targets.

Authors:  G Harth; M A Horwitz
Journal:  J Exp Med       Date:  1999-05-03       Impact factor: 14.307

10.  A second-generation anti TB vaccine is long overdue.

Authors:  Mauricio Castañón-Arreola; Yolanda López-Vidal
Journal:  Ann Clin Microbiol Antimicrob       Date:  2004-06-03       Impact factor: 3.944
View more
  18 in total

Review 1.  Prospects in Mycobacterium bovis Bacille Calmette et Guérin (BCG) vaccine diversity and delivery: why does BCG fail to protect against tuberculosis?

Authors:  Juan I Moliva; Joanne Turner; Jordi B Torrelles
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

2.  Methionine sulfoximine resistance in Mycobacterium tuberculosis is due to a single nucleotide deletion resulting in increased expression of the major glutamine synthetase, GlnA1.

Authors:  Paul Carroll; Simon J Waddell; Philip D Butcher; Tanya Parish
Journal:  Microb Drug Resist       Date:  2011-09       Impact factor: 3.431

3.  Arginine-deprivation-induced oxidative damage sterilizes Mycobacterium tuberculosis.

Authors:  Sangeeta Tiwari; Andries J van Tonder; Catherine Vilchèze; Vitor Mendes; Sherine E Thomas; Adel Malek; Bing Chen; Mei Chen; John Kim; Tom L Blundell; Julian Parkhill; Brian Weinrick; Michael Berney; William R Jacobs
Journal:  Proc Natl Acad Sci U S A       Date:  2018-08-24       Impact factor: 11.205

4.  Functional analysis of GlnE, an essential adenylyl transferase in Mycobacterium tuberculosis.

Authors:  Paul Carroll; Carey A Pashley; Tanya Parish
Journal:  J Bacteriol       Date:  2008-05-09       Impact factor: 3.490

5.  Mode-of-action profiling reveals glutamine synthetase as a collateral metabolic vulnerability of M. tuberculosis to bedaquiline.

Authors:  Zhe Wang; Vijay Soni; Gwendolyn Marriner; Takushi Kaneko; Helena I M Boshoff; Clifton E Barry; Kyu Y Rhee
Journal:  Proc Natl Acad Sci U S A       Date:  2019-09-09       Impact factor: 11.205

6.  A Replication-Limited Recombinant Mycobacterium bovis BCG vaccine against tuberculosis designed for human immunodeficiency virus-positive persons is safer and more efficacious than BCG.

Authors:  Michael V Tullius; Günter Harth; Sasa Maslesa-Galic; Barbara J Dillon; Marcus A Horwitz
Journal:  Infect Immun       Date:  2008-08-25       Impact factor: 3.441

7.  A fragment-based approach to assess the ligandability of ArgB, ArgC, ArgD and ArgF in the L-arginine biosynthetic pathway of Mycobacterium tuberculosis.

Authors:  Pooja Gupta; Sherine E Thomas; Shaymaa A Zaidan; Maria A Pasillas; James Cory-Wright; Víctor Sebastián-Pérez; Ailidh Burgess; Emma Cattermole; Clio Meghir; Chris Abell; Anthony G Coyne; William R Jacobs; Tom L Blundell; Sangeeta Tiwari; Vítor Mendes
Journal:  Comput Struct Biotechnol J       Date:  2021-06-04       Impact factor: 7.271

8.  High throughput phenotypic analysis of Mycobacterium tuberculosis and Mycobacterium bovis strains' metabolism using biolog phenotype microarrays.

Authors:  Bhagwati Khatri; Mark Fielder; Gareth Jones; William Newell; Manal Abu-Oun; Paul R Wheeler
Journal:  PLoS One       Date:  2013-01-10       Impact factor: 3.240

9.  13C-flux spectral analysis of host-pathogen metabolism reveals a mixed diet for intracellular Mycobacterium tuberculosis.

Authors:  Dany J V Beste; Katharina Nöh; Sebastian Niedenführ; Tom A Mendum; Nathaniel D Hawkins; Jane L Ward; Michael H Beale; Wolfgang Wiechert; Johnjoe McFadden
Journal:  Chem Biol       Date:  2013-08-01

10.  Genome-Wide Essentiality Analysis of Mycobacterium abscessus by Saturated Transposon Mutagenesis and Deep Sequencing.

Authors:  Dalin Rifat; Liang Chen; Barry N Kreiswirth; Eric L Nuermberger
Journal:  mBio       Date:  2021-06-15       Impact factor: 7.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.